CN108524678A - A kind of tea seed cake is used as inhibitor for squalene synthetic enzyme and the purposes for lipid-loweringing - Google Patents
A kind of tea seed cake is used as inhibitor for squalene synthetic enzyme and the purposes for lipid-loweringing Download PDFInfo
- Publication number
- CN108524678A CN108524678A CN201810769428.0A CN201810769428A CN108524678A CN 108524678 A CN108524678 A CN 108524678A CN 201810769428 A CN201810769428 A CN 201810769428A CN 108524678 A CN108524678 A CN 108524678A
- Authority
- CN
- China
- Prior art keywords
- tea seed
- seed cake
- squalene
- inhibitor
- lipid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 title claims abstract description 22
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 title claims abstract description 22
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 title claims abstract description 22
- 229940031439 squalene Drugs 0.000 title claims abstract description 22
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 title claims abstract description 22
- 108090000790 Enzymes Proteins 0.000 title claims abstract description 14
- 102000004190 Enzymes Human genes 0.000 title claims abstract description 14
- 239000003112 inhibitor Substances 0.000 title claims abstract description 14
- 241001122767 Theaceae Species 0.000 title claims abstract 9
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims abstract description 28
- 241001596328 Camellia meiocarpa Species 0.000 claims abstract description 27
- 239000003814 drug Substances 0.000 claims abstract description 17
- 229940079593 drug Drugs 0.000 claims abstract description 16
- 235000013305 food Nutrition 0.000 claims abstract description 16
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims abstract description 5
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims description 2
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 210000001367 artery Anatomy 0.000 claims 1
- 108010022535 Farnesyl-Diphosphate Farnesyltransferase Proteins 0.000 abstract description 8
- 235000012000 cholesterol Nutrition 0.000 abstract description 7
- 230000000694 effects Effects 0.000 abstract description 7
- XQRLCLUYWUNEEH-UHFFFAOYSA-N diphosphonic acid Chemical compound OP(=O)OP(O)=O XQRLCLUYWUNEEH-UHFFFAOYSA-N 0.000 abstract description 4
- ATZKAUGGNMSCCY-VYCBRMPGSA-N presqualene diphosphate Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\[C@H]1[C@H](COP(O)(=O)OP(O)(O)=O)[C@@]1(C)CC\C=C(/C)CCC=C(C)C ATZKAUGGNMSCCY-VYCBRMPGSA-N 0.000 abstract description 4
- 230000015572 biosynthetic process Effects 0.000 abstract description 3
- 230000002401 inhibitory effect Effects 0.000 abstract description 3
- ACFIXJIJDZMPPO-NNYOXOHSSA-N NADPH Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](OP(O)(O)=O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 ACFIXJIJDZMPPO-NNYOXOHSSA-N 0.000 abstract description 2
- 238000006471 dimerization reaction Methods 0.000 abstract description 2
- 239000001177 diphosphate Substances 0.000 abstract description 2
- 235000011180 diphosphates Nutrition 0.000 abstract description 2
- -1 farnesyl diphosphates Chemical class 0.000 abstract description 2
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 abstract description 2
- 230000009467 reduction Effects 0.000 abstract description 2
- 230000004060 metabolic process Effects 0.000 abstract 1
- 244000269722 Thea sinensis Species 0.000 description 20
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 230000014509 gene expression Effects 0.000 description 6
- 150000002632 lipids Chemical class 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 235000013399 edible fruits Nutrition 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 210000002381 plasma Anatomy 0.000 description 4
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 150000003626 triacylglycerols Chemical class 0.000 description 3
- 108010023302 HDL Cholesterol Proteins 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 1
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 241000209507 Camellia Species 0.000 description 1
- 238000008620 Cholesterol Assay Methods 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 235000006468 Thea sinensis Nutrition 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 238000012925 biological evaluation Methods 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000018597 common camellia Nutrition 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 150000008584 quinuclidines Chemical class 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000004059 squalene synthase inhibitor Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- Botany (AREA)
- Nutrition Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Food Science & Technology (AREA)
- Cardiology (AREA)
- Polymers & Plastics (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
It is used as inhibitor for squalene synthetic enzyme the invention discloses a kind of tea seed cake and for the purposes of lipid-loweringing.It is a discovery of the invention that the tea seed cake of camellia meiocarpa is effective inhibitor of squalene synthetase.Squalene synthetase be cholesterol biosynthesis, metabolism a kind of important enzyme, it can be catalyzed two molecule farnesyl diphosphates through reproducibility dimerization, intermediate presqualene diphosphonic acid be generated, under NADPH reductions, presqualene diphosphonic acid generates squalene, the latter's further synthetic cholesterol.Inhibit squalene synthetase activity that can reduce cholesterol levels.Moreover, it has been also reported that, inhibitor for squalene synthetic enzyme can not only reduce cholesterol levels, also reduce triglyceride levels, and then reach lipid-lowering effect.Therefore, the tea seed cake of camellia meiocarpa can be prepared into the food, drug or health products of lipid-loweringing by inhibiting squalene synthetase to play effect for reducing fat.
Description
Technical field
It is used as inhibitor for squalene synthetic enzyme the present invention relates to the tea seed cake of camellia meiocarpa and for the purposes of lipid-loweringing.
Background technology
Camellia meiocarpa (Camellia meiocarpa Hu.) also known as Jiangxi, small tea, heart, Camellia yuansienensis, sheep dung
Son etc..Fruit is small, leaf is small, bud is small, and it is its notable feature that bud, bract, which do not have hair,.Camellia meiocarpa it is resistance to it is shady, fruit is small, thin skin, yield are high,
Its cultivated area and annual output are only second to C. olelfera, are distributed in the provinces such as Fujian, Jiangxi, Guangxi, Hunan, Guizhou, Jiangsu and Zhejiang Provinces.
Chemical composition contained by camellia meiocarpa mainly has saponin(e, flavones, polyphenol, polysaccharide and protein compound etc..Pharmacology is ground
Study carefully and show that oil tea plant not only has antibacterial, anti-inflammatory, clearing heat and detoxicating and other effects, but also is also shown anti-oxidant, antitumor etc.
Preferable bioactivity is shown, wherein Sasanguasaponin is notable to the pharmacological activity of cardiovascular and cerebrovascular, however camellia meiocarpa and Related Drug
It is seldom to manage active reporter.
Invention content
It is used as inhibitor for squalene synthetic enzyme the purpose of the present invention is to provide the tea seed cake of camellia meiocarpa and for lipid-loweringing
Purposes.
The above-mentioned purpose of the present invention is achieved by following technical solution：
The tea seed cake of camellia meiocarpa is used as the purposes of inhibitor for squalene synthetic enzyme.
The tea seed cake of camellia meiocarpa is used to prepare the purposes of the food, drug or health products that reduce cholesterol levels.
The tea seed cake of camellia meiocarpa is used to prepare the purposes of the food, drug or health products that reduce triglyceride levels.
The tea seed cake of camellia meiocarpa is used to prepare the purposes of the food of lipid-loweringing, drug or health products.
The tea seed cake of camellia meiocarpa is used to prepare the use of the food of prevention hyperlipidemia and its caused disease, drug or health products
On the way.
Further, disease caused by hyperlipidemia includes hyperlipidemia, atherosclerosis, nonalcoholic fatty liver.
A kind of inhibitor for squalene synthetic enzyme, the tea seed cake containing camellia meiocarpa, also containing can in food, drug or health products
With the carrier or excipient of receiving, acceptable dosage form in food, drug or health products is made.
It is a discovery of the invention that the tea seed cake of camellia meiocarpa is effective inhibitor of squalene synthetase.Squalene synthetase is body
A kind of important enzyme in inner cholesterol synthesis, metabolic pathway, it can be catalyzed two molecule farnesyl diphosphates through reproducibility dimerization
With, intermediate presqualene diphosphonic acid is generated, under the reduction of NADPH, presqualene diphosphonic acid generation squalene, the latter
Again through being further synthetically generated cholesterol.Inhibit squalene synthetase activity that can reduce cholesterol levels.It is reported moreover, also having
Road points out that inhibitor for squalene synthetic enzyme can not only reduce cholesterol levels, also reduces triglyceride levels (bibliography：
Synthesis and biological evaluation of quinuclidine derivatives incorporating
phenothiazine moieties as squalene synthase inhibitors.Chem Pharm Bull,2004,
52:1204-1209), and then reach lipid-lowering effect.Therefore, the tea seed cake of camellia meiocarpa can be by inhibiting squalene synthetase hair
Wave effect for reducing fat.
Specific implementation mode
Essentiality content of the present invention is specifically introduced with reference to embodiment.
One, experiment material
Take the tea fruit of camellia meiocarpa to clean, air-dry after squeezing deoil after the tea seed cake of camellia meiocarpa is prepared.
C57BL/6J male mices, 18~22g of weight are purchased from Beijing Vital River Experimental Animals Technology Co., Ltd..
Illumination 12h, dark 12h place mouse 5 per cage.Chow diet, high lipid food (D12492,60kcal%) are purchased from Jiangsu Province
Cooperate with medical bioengineering Co., Ltd.
Two, experimental method
1, modeling, grouping and administration
After C57BL/6J male mices adaptable fed 1 week, mouse is numbered by weight, using random table by mouse
It is divided into blank control group and modeling group, gives corresponding experiment feed diet.Model control group and tea seed cake is low, high dose group is (small
Fruit Extracted From Oil-tea-cake 50,100mg/kg), every group 10, sub-cage rearing gives high lipid food nursing in addition to blank group.It weighs within every 7 days
One time weight adjusts dosage, and blank control group and model control group give isometric solvent, and the daily gavage of each group mouse is given
Relative medicine 1 time, successive administration 10w.
2, lipid determination
It cuts tail and takes total cholesterol, triglycerides, high-density lipoprotein cholesterol and low-density lipoprotein in hematometry blood plasma
White cholesterol.Plasma triglyceride, total cholesterol assay kit are purchased from Shanghai Kehua Bio-engineering Co., Ltd, blood plasma
Low density lipoprotein cholesterol, high-density lipoprotein cholesterol, glutamic-pyruvic transaminase, glutamic-oxalacetic transaminease assay kit are purchased from Nanjing
Bioengineering Research Institute is built up, determination step is carried out by corresponding instructions.
3, squalene expression measures
Last time administration cuts tail and blood is taken to take liver, -80 DEG C of refrigerators to freeze spare for after surveying blood fat, putting to death mouse.
The total serum IgE in liver is extracted by Trizol one-step method, onedrop surveys its purity and concentration, wherein OD260/OD280
It is preferable that its purity is represented 1.8~2.0.After extracting total serum IgE, promise only praises reverse transcription reagent box and carries out reverse transcription acquisition cDNA, instead
It is expanded according to RT-PCR reaction systems after transcription, using GAPDH as internal reference, carries out the quantitative analysis of PCR product.
Primer sequence is：
Squalene sense primer：5'-AGAGTGGCGGTTCACTGAGA-3'；
Squalene downstream primer：5'-GAGAAAGGCCAATTCCCACCA-3'；
GAPDH sense primers：5'-TGTGTCCGTCGTGGATCTGA-3'；
GAPDH downstream primers：5'-CCTGCTTCACCACCTTCTTGAT-3'.
PCR reaction conditions：95 DEG C of pre-degeneration 10min, 95 DEG C of denaturation 15s, 60 DEG C of annealing 30s, 75 DEG C of extension 30s, 75 DEG C
Ultimate extension 1min, totally 45 recycle.Using 2-ΔΔCtMethod calculates the relative expression levels of squalene mRNA.
4, data processing and inversion
Using SPSS19.0 softwares, more comparison among groups are examined using one-way analysis of variance, are compared two-by-two between group and are examined using q
It tests.It is that difference is statistically significant with P ＜ 0.05.
Three, experimental result
1, squalene expression comparison result in each group mouse liver tissue
Compared with model group, tea seed cake is low, squalene mRNA expressions significantly reduce (P ＜ in high dose group liver organization
0.05), and degree and the certain dependence of tea seed cake dosage presentation are reduced.It the results are shown in Table 1 (note：The * p compared with blank control group<
0.05, * * p<0.01, * * * p<0.001；Compared with model control group#p<0.05,##p<0.01,###p<0.001)。
Squalene mRNA relative expression levels compare in 1 each group mice serum of table and liver organization
2, the horizontal comparison result of each group lipid of mice
Compared with model group, tea seed cake is low, high dose group total plasma cholesterol, triglycerides significantly reduce, and reduces degree
Certain dependence is presented with tea seed cake dosage.It the results are shown in Table 2 (notes：The * p compared with blank control group<0.05, * * p<
0.01, * * * p<0.001；Compared with model control group#p<0.05,##p<0.01,###p<0.001)。
2 each group lipid of mice of table is horizontal
The above results show the camellia meiocarpa dregs of rice by inhibiting the expression of squalene to significantly reduce the total of high blood lipid model mouse
Cholesterol, triglycerides can be prepared into food, drug or the health products of prevention high blood ester.In addition, the camellia meiocarpa dregs of rice can be with
As the positive drug for screening other inhibitor for squalene synthetic enzyme.
The effect of above-described embodiment is specifically to introduce the essentiality content of the present invention, but those skilled in the art should know
Protection scope of the present invention should not be confined to the specific embodiment by road.
Claims (7)
1. the tea seed cake of camellia meiocarpa is used as the purposes of inhibitor for squalene synthetic enzyme.
2. the tea seed cake of camellia meiocarpa is used to prepare the purposes of the food, drug or health products that reduce cholesterol levels.
3. the tea seed cake of camellia meiocarpa is used to prepare the purposes of the food, drug or health products that reduce triglyceride levels.
4. the tea seed cake of camellia meiocarpa is used to prepare the purposes of the food of lipid-loweringing, drug or health products.
5. the tea seed cake of camellia meiocarpa is used to prepare the use of the food of prevention hyperlipidemia and its caused disease, drug or health products
On the way.
6. purposes according to claim 5, it is characterised in that：Disease caused by hyperlipidemia includes hyperlipidemia, artery congee
Sample hardening, nonalcoholic fatty liver.
7. a kind of inhibitor for squalene synthetic enzyme, it is characterised in that：Tea seed cake containing camellia meiocarpa, also contain food, drug or
Acceptable dosage form in food, drug or health products is made in acceptable carrier or excipient in health products.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810769428.0A CN108524678A (en) | 2018-07-13 | 2018-07-13 | A kind of tea seed cake is used as inhibitor for squalene synthetic enzyme and the purposes for lipid-loweringing |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810769428.0A CN108524678A (en) | 2018-07-13 | 2018-07-13 | A kind of tea seed cake is used as inhibitor for squalene synthetic enzyme and the purposes for lipid-loweringing |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108524678A true CN108524678A (en) | 2018-09-14 |
Family
ID=63488260
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810769428.0A Pending CN108524678A (en) | 2018-07-13 | 2018-07-13 | A kind of tea seed cake is used as inhibitor for squalene synthetic enzyme and the purposes for lipid-loweringing |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108524678A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1475249A (en) * | 2002-08-13 | 2004-02-18 | 田维熙 | Fatty acid synthetic enzyme inhibitor and its production method and application |
| US20070128300A1 (en) * | 2004-01-29 | 2007-06-07 | Nam Jong H | Natural tea having effects of hangover relief and liver function recovery and method for preparing the same |
-
2018
- 2018-07-13 CN CN201810769428.0A patent/CN108524678A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1475249A (en) * | 2002-08-13 | 2004-02-18 | 田维熙 | Fatty acid synthetic enzyme inhibitor and its production method and application |
| CN1332687C (en) * | 2002-08-13 | 2007-08-22 | 田维熙 | Fatty acid synthetic enzyme inhibitor and its production method and application |
| US20070128300A1 (en) * | 2004-01-29 | 2007-06-07 | Nam Jong H | Natural tea having effects of hangover relief and liver function recovery and method for preparing the same |
Non-Patent Citations (3)
| Title |
|---|
| 李梦丹: "茶油籽粕的综合利用", 《粮食与油脂》 * |
| 顾觉奋: "角鲨烯合成酶抑制剂降血脂作用及机制的研究进展", 《药学进展》 * |
| 龚吉军: "油茶粕多肽降血脂活性研究", 《食品研究与开发》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Li et al. | Astaxanthin in liver health and disease: a potential therapeutic agent | |
| Shimatsu et al. | Clinical application of “curcumin”, a multi-functional substance | |
| CN102524536B (en) | Application of theaflavin as feed additive and corresponding feed | |
| CN107921052A (en) | Suppress the method that lipid absorbs and/or promote lipid to drain using D psicoses | |
| Noreen et al. | Health benefits of buckwheat (Fagopyrum esculentum), potential remedy for diseases, rare to cancer: A mini review | |
| Liu et al. | Enhancement of broccoli indole glucosinolates by methyl jasmonate treatment and effects on prostate carcinogenesis | |
| Han et al. | Pharmacological and pharmacokinetic studies with agaricoglycerides, extracted from Grifola frondosa, in animal models of pain and inflammation | |
| CN105395565A (en) | Application of ginsenoside F2 in preventing or treating liver diseases | |
| KR20110095486A (en) | A composition for anti-cholesterolemia or anti-obesity activity containing the polyphenol extracts from phellinus baumii | |
| Ayyadurai et al. | Bioactive compounds in green tea may improve transplant tolerance: A computational systems biology analysis | |
| De Sousa Lages et al. | Therapeutics that can potentially replicate or augment the anti-aging effects of physical exercise | |
| CN1902189A (en) | Plant-origin beta3-adrenoceptor agonist and use of the same | |
| Duan et al. | Antitumor effects and mechanism of n-butanol fraction from aril of Torreya grandis in H22 mice | |
| CN101808654B (en) | Compounds extracted from palm oil mill effluent for the treatment of cancer, compositions thereof and methods therewith | |
| CN108524678A (en) | A kind of tea seed cake is used as inhibitor for squalene synthetic enzyme and the purposes for lipid-loweringing | |
| CN104415135B (en) | The purposes of hydroxyl polymethoxyflavone class compound and/or its derivative | |
| Hussein et al. | The Potential Therapeutic Effects of Marine Algae (Ulva lactuca & Corallina elongata) Crude Extracts on Alloxan-induced Diabetic Albino Rats. | |
| Xu-Zhen et al. | Effects of maslinic acid as a novel glycogen phosphorylase inhibitor on blood glucose and hepatic glycogen in mice | |
| WO2009145411A2 (en) | Compositions for preventing or treating colon cancer comprising extracts from thorns of gleditsia sinensis | |
| Romero-Martínez et al. | Main mechanisms of action of policosanol in animal and plant cells | |
| Xu et al. | Functional properties of dietary quercetin in cardiovascular health and disease | |
| JP2012031153A (en) | Fat combustion promoting agent | |
| Singh et al. | Glycolytic Inhibitors as Caloric Restriction Mimetics (CRM) | |
| Cui et al. | Advances in the global distribution, chemical constituents, and pharmacology of hippocampus, a traditional marine Chinese medicine | |
| US20090292012A1 (en) | Therapeutic Agent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180914 |
|
| RJ01 | Rejection of invention patent application after publication |